An isolated polynucleotide comprising: a first nucleotide sequence encoding a first antigenic polypeptide, wherein the first antigenic polypeptide: a. comprises an amino acid sequence that has at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 29； b. is capable of initiating an immune response against the first oncogenic viral polypeptide in an immunocompetent host； and c. it is not oncogenic in the immunocompetent host； and a second nucleotide sequence encoding a second antigenic polypeptide, wherein the second antigenic polypeptide: a. comprises an amino acid sequence that has at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 30； b. is capable of initiating an immune response against the second oncogenic viral polypeptide in an immunocompetent host； and c. it is not oncogenic in the immunocompetent host； wherein the first antigenic polypeptide has the following mutations with respect to SEQ ID NO: 2: a. a point mutation or deletion in L50； b. a point mutation or deletion in E148； C. a point mutation or deletion in T149； d. a point mutation or deletion in Q150； and e. a point mutation or deletion in L151； and wherein the second antigenic polypeptide has the following mutations with respect to SEQ ID NO: 4: a. a point mutation or deletion in H2； b. a point mutation or deletion in C24； C. a point mutation or deletion in E46； and d. a point mutation or deletion in L67.Un polinucleótido aislado que comprende: una primera secuencia de nucleótidos que codifica un primer polipéptido antigénico, en el que el primer polipéptido antigénico: a. comprende una secuencia de aminoácidos que tiene al menos 70 % de identidad de secuencia con la secuencia de aminoácidos de la SEQ ID NO:29； b. es capaz de iniciar una respuesta inmunitaria contra el primer polipéptido vírico oncogénico en un hospedador inmunocompetente； y c. no es oncogénico en el hospedador inmunocompetente； y una segunda secuencia de nucleótidos que codifica un segundo
